Abstract
Background Aberrant brain connectivity during emotional processing, especially within the fronto-limbic pathway, is one of the hallmarks of major depressive disorder (MDD). However, a lack of systematic approaches in previous studies made it difficult to determine whether a specific alteration in brain connectivity reflects a cause, correlate, or effect of the disorder. The current study aimed to investigate neural mechanisms that correspond to disease, risk and resilience in major depression during implicit processing of emotion cues.
Methods Forty-eight patients with MDD, 49 first-degree relatives of patients with MDD and 103 healthy controls performed a face-matching task during functional magnetic resonance imaging. We used dynamic causal modelling to estimate task-dependent effective connectivity at the subject level. Parametric empirical Bayes was then performed to quantify group differences in effective connectivity.
Results Depressive pathology was associated with decreased effective connectivity from the left amygdala and left dorsolateral prefrontal cortex to the right fusiform gyrus, whereas familial risk for depression corresponded to decreased connectivity from the right orbitofrontal cortex to the left insula and from the left orbitofrontal cortex to the right fusiform gyrus. Resilience for depression was related to increased connectivity from the anterior cingulate cortex to the left dorsolateral prefrontal cortex.
Conclusions Our results suggest that the depressive state alters top-down control of higher visual regions during the processing of emotional faces, whereas increased connectivity within the cognitive control network promotes resilience to depression.
Competing Interest Statement
A.M.-L. has received consultant fees from Boehringer Ingelheim, Elsevier, Walt Disney Pictures,Brainsway, Lundbeck Int. Neuroscience Foundation, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum fuer Neurodegenerative Erkrankungen, Universitaet Zurich, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, and has received fees for lectures, interviews and travels from Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, Institut d'investigacions Biomediques August Pi i Sunyer (IDIBAPS), Jansen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer, Atheneum, Universitaet Freiburg, Schizophrenia Academy, Hong Kong Society 21 of Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry, Reunions I Ciencia S.L., Brain Center Rudolf Magnus UMC Utrecht. All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This work was funded by the German Federal Ministry for Education and Research (BMBF) grants NGFNplus MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia) and the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of th e:Med program (grant numbers O1ZX1314B and O1ZX1314G). A.R. is funded by the Australian Research Council (Refs: DE170100128 and DP200100757) and Australian National Health and Medical Research Council Investigator Grant (Ref: 1194910).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki and reviewed and approved by the local ethics committees of the participating study sites: The ethics committee of Charite-Universitaetsmedizin Berlin, Germany; the ethics committee of the Central Institute of Mental Health, Mannheim, Germany; and the ethics committee of the Faculty of Medicine at the University of Bonn, Bonn, Germany.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data of the current study are available from the corresponding author,[C.W],upon reasonable request.
